Javier Araiza
Research Subjects
Javier Araiza has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Alexandro Bonifaz
Department of Dermatology, General Hospital of Mexico, Mexico City, Mexico
15 shared publications - Andrés Tirado-Sánchez
Dermatology Service, Mycology Department, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico
9 shared publications - Gloria González
Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
4 shared publications Leonel Fierro-Arias
Dermatology Service and Mycology Department, Hospital General de México ‘Dr. Eduardo Liceaga’ , Mexico City
3 shared publications- Alejandro Hernández-Solís
Universidad Nacional Autónoma de México (UNAM), Facultad de Medicina Mexico City Mexico
2 shared publications - David John Chandler
Dermatology Department, Brighton General Hospital, University Hospitals Sussex NHS Foundation Trust , Brighton
2 shared publications
Latest Publications
- 1 June 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 62, 101159
Cryptococcosis mimicking lung cancer in an immunocompetent patient: A case report
- 1 June 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 62, 101159
Cryptococcosis mimicking lung cancer in an immunocompetent patient: A case report
- 14 May 2026
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 20 (1)
Onychomycosis in the Elderly: Diagnosis and Treatment Challenges
- 14 May 2026
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 20 (1)
Onychomycosis in the Elderly: Diagnosis and Treatment Challenges
- Open Access
- 16 December 2025
- Published by Instituto Mexicano del Seguro Social in Medicina Cutánea Ila
- Vol. 53 (3) , 67-68
What is changing in medical mycology?
- 16 December 2025
- Published by Instituto Mexicano del Seguro Social in Medicina Cutánea Ila
- Vol. 53 (3) , 67-68
Open AccessWhat is changing in medical mycology?
- Open Access
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 983-986
Tratamento de eumicetoma com terbinafina isoladamente e em combinação como terapia de resgate
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 983-986
Open AccessTratamento de eumicetoma com terbinafina isoladamente e em combinação como terapia de resgate
- 22 August 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (1) , 182-184
Tinea capitis in older people: clinical experience of 36 cases over 10 years
Tinea capitis in older people is rare. Here, we describe our experience of 36 cases of tinea capitis in older individuals over a 10-year period. We present clinical, mycological and treatment characteristics.
- 22 August 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (1) , 182-184
Tinea capitis in older people: clinical experience of 36 cases over 10 years
Tinea capitis in older people is rare. Here, we describe our experience of 36 cases of tinea capitis in older individuals over a 10-year period. We present clinical, mycological and treatment characteristics.
- Open Access
- 7 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 983-986
Treatment of eumycetoma with terbinafine alone and in combination with salvage therapy
- 7 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 983-986
Open AccessTreatment of eumycetoma with terbinafine alone and in combination with salvage therapy
- Open Access
- 28 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae385
Clinical and Biochemical Characteristics of Hemophagocytic Lymphohistiocytosis in People Living With HIV and Disseminated Histoplasmosis at a Tertiary Hospital in Mexico
Hemophagocytic lymphohistiocytosis (HLH) is considered a rare disease with high morbidity and mortality risks. Most research on this disease is conducted in pediatric settings. Therefore, this study aimed to describe the clinical characteristics, laboratory findings, and outcomes related to HLH in people living with human immunodeficiency virus (HIV)/AIDS) and disseminated histoplasmosis. A retrospective and descriptive study was conducted in a tertiary hospital in México City from January 2018 to December 2022, including people living with HIV who had disseminated histoplasmosis confirmed through direct microbiological or immunological methods with an HScore ≥169 or who met 5 of the 8 HLH-2004 criteria. HLH occurred in 36.1% (n = 26) of patients with HIV and disseminated histoplasmosis; the majority were men (84.9%), and their mean age (standard deviation) was 30.19 (5.6) years. The most frequent clinical manifestations were hepatomegaly (100%), fever (96.2%), and dyspnea (84.6%). The most common biochemical changes were hyperferritinemia (100%), elevated lactate dehydrogenase (100%), and bicytopenia (61.5%). Partial thromboplastin time (P = .012) and prothrombin time (P = .004) were associated with the 30-day mortality rate, and the 30-day survival rate was 65.4%. We detected a high frequency of HLH; therefore, we encourage physicians to use diagnostic prediction tools (HLH-2004 and HScore criteria) in each reassessment for timely detection.
- 28 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae385
Open AccessClinical and Biochemical Characteristics of Hemophagocytic Lymphohistiocytosis in People Living With HIV and Disseminated Histoplasmosis at a Tertiary Hospital in Mexico
Hemophagocytic lymphohistiocytosis (HLH) is considered a rare disease with high morbidity and mortality risks. Most research on this disease is conducted in pediatric settings. Therefore, this study aimed to describe the clinical characteristics, laboratory findings, and outcomes related to HLH in people living with human immunodeficiency virus (HIV)/AIDS) and disseminated histoplasmosis. A retrospective and descriptive study was conducted in a tertiary hospital in México City from January 2018 to December 2022, including people living with HIV who had disseminated histoplasmosis confirmed through direct microbiological or immunological methods with an HScore ≥169 or who met 5 of the 8 HLH-2004 criteria. HLH occurred in 36.1% (n = 26) of patients with HIV and disseminated histoplasmosis; the majority were men (84.9%), and their mean age (standard deviation) was 30.19 (5.6) years. The most frequent clinical manifestations were hepatomegaly (100%), fever (96.2%), and dyspnea (84.6%). The most common biochemical changes were hyperferritinemia (100%), elevated lactate dehydrogenase (100%), and bicytopenia (61.5%). Partial thromboplastin time (P = .012) and prothrombin time (P = .004) were associated with the 30-day mortality rate, and the 30-day survival rate was 65.4%. We detected a high frequency of HLH; therefore, we encourage physicians to use diagnostic prediction tools (HLH-2004 and HScore criteria) in each reassessment for timely detection.
- 1 January 2024
- Published by Our Dermatology Online in Our Dermatology Online
- Vol. 15 (1)
utaneous verrucose phaeohyphomycosis due to Exophiala oligosperma in an immunocompetent host
Herein, we report a case of subcutaneous infection caused by Exophiala oligosperma. A verrucous plaque was the major clinical feature. A histopathological examination revealed features of suppurative granuloma. Mycological and molecular identification revealed E. oligosperma as the etiologic agent. After eight months of treatment, the lesion showed worsening due to the use of self-medication with topical hydrocortisone. A second biopsy was performed with direct examination (KOH 10%) showing dark pigmented septate hyphae, yeast and multiple dark hyphae were highlighted in biopsy with Gomori methenamine silver (GMS) staining. We report this case to show the rise of this infection in an immunocompetent patient and the effects of steroids. The patient was treated with itraconazole and cryosurgery. Key words: Phaeohyphomycosis, Cutaneous, Verrucose, Exophiala oligosperma, Melanized fungi, Immunocompetent host, Itraconazole, Cryosurgery, Chromoblastomycosis
- 1 January 2024
- Published by Our Dermatology Online in Our Dermatology Online
- Vol. 15 (1)
utaneous verrucose phaeohyphomycosis due to Exophiala oligosperma in an immunocompetent host
Herein, we report a case of subcutaneous infection caused by Exophiala oligosperma. A verrucous plaque was the major clinical feature. A histopathological examination revealed features of suppurative granuloma. Mycological and molecular identification revealed E. oligosperma as the etiologic agent. After eight months of treatment, the lesion showed worsening due to the use of self-medication with topical hydrocortisone. A second biopsy was performed with direct examination (KOH 10%) showing dark pigmented septate hyphae, yeast and multiple dark hyphae were highlighted in biopsy with Gomori methenamine silver (GMS) staining. We report this case to show the rise of this infection in an immunocompetent patient and the effects of steroids. The patient was treated with itraconazole and cryosurgery. Key words: Phaeohyphomycosis, Cutaneous, Verrucose, Exophiala oligosperma, Melanized fungi, Immunocompetent host, Itraconazole, Cryosurgery, Chromoblastomycosis
Review Article White Piedra: Review of 131 cases
This study analyzes the clinical characteristics of patients diagnosed with White Piedra through a systematic review of cases in the literature. A sample of 131 subjects was considered, of which 91.6% were female and most were 18 years of age or younger. Most studies were conducted in Brazil, followed by India, and Mexico. The most common etiologic agent found was Trichosporon spp (34.3%). Most affected patients were asymptomatic (94.6%) and predisposing factors included long hair, use of a hair band or hair accessories, and wet hair. The most common clinical feature was the presence of nodules. The evaluation of treatment effectiveness was hindered by the scarcity of follow‐up information in the majority of the studies. It is concluded that White Piedra infection is more common in young women and is associated with hair‐related factors.
Review Article White Piedra: Review of 131 cases
This study analyzes the clinical characteristics of patients diagnosed with White Piedra through a systematic review of cases in the literature. A sample of 131 subjects was considered, of which 91.6% were female and most were 18 years of age or younger. Most studies were conducted in Brazil, followed by India, and Mexico. The most common etiologic agent found was Trichosporon spp (34.3%). Most affected patients were asymptomatic (94.6%) and predisposing factors included long hair, use of a hair band or hair accessories, and wet hair. The most common clinical feature was the presence of nodules. The evaluation of treatment effectiveness was hindered by the scarcity of follow‐up information in the majority of the studies. It is concluded that White Piedra infection is more common in young women and is associated with hair‐related factors.
- Open Access
- 31 August 2023
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 43 (Sp. 1) , 97-108
Candidiasis oral mixta en pacientes con diabetes de tipo 2: identificación y espectro de sensibilidad
Introducción. Los pacientes con diabetes mellitus de tipo 2 son propensos a adquirir infecciones por Candida spp., en ocasiones, causadas por más de una especie. La resistencia de algunas de ellas puede resultar en complicaciones médicas por falla del tratamiento.Objetivos. Determinar la frecuencia y las variedades clínicas de la candidiasis oral mixta en pacientes con diabetes mellitus de tipo 2, las especies de Candida involucradas y sus espectros de sensibilidad a los antifúngicos utilizados como tratamiento.Material y métodos. Se hizo un estudio transversal analítico en pacientes con diabetes mellitus de tipo 2, hiperglucemia (superior o igual al 7 % de la hemoglobina glucosilada, HbA1C) y con diagnóstico clínico de candidiasis oral. Mediante técnicas microbiológicas, se identificaron las especies causales de la candidiasis oral. Las pruebas de sensibilidad se llevaron a cabo con el método de difusión en placa con tiras (E-test®).Resultados. Se incluyeron 72 pacientes: 32 (44 %) hombres y 40 (56 %) mujeres, clasificados en tres grupos de edad: jóvenes adultos (17 %), adultos (74 %) y ancianos (9 %), con una media de 51 años. No se encontraron diferencias significativas en la candidiasis oral según los grupos de sexo y edad, ni entre las candidiasis orales mixtas y el sexo, el porcentaje de HbA1C, el tratamiento antihiperglucemiante o el tiempo de diagnóstico de la diabetes mellitus de tipo 2. En el grupo etario de adultos, se encontró una correlación con las candidiasis mixtas o simples. Se encontraron 8 (13 %) casos de candidiasis mixtas: siete con coinfección por dos especies de Candida y uno con coinfección por tres especies. Las especies identificadas en ellos, fueron: Candida albicans, C. glabrata, C. dubliniensis, C. kefyr, C. tropicalis y C. krusei. La mayoría de estas especies presentó sensibilidad a ketoconazol y fluconazol, y mayor resistencia a itraconazol.Conclusiones. Las candidiasis orales mixtas se presentan, aproximadamente, en el 10 % de los pacientes con diabetes mellitus de tipo 2 y el tratamiento puede ser ineficaz cuando no se identifica el agente etiológico.
- 31 August 2023
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 43 (Sp. 1) , 97-108
Open AccessCandidiasis oral mixta en pacientes con diabetes de tipo 2: identificación y espectro de sensibilidad
Introducción. Los pacientes con diabetes mellitus de tipo 2 son propensos a adquirir infecciones por Candida spp., en ocasiones, causadas por más de una especie. La resistencia de algunas de ellas puede resultar en complicaciones médicas por falla del tratamiento.Objetivos. Determinar la frecuencia y las variedades clínicas de la candidiasis oral mixta en pacientes con diabetes mellitus de tipo 2, las especies de Candida involucradas y sus espectros de sensibilidad a los antifúngicos utilizados como tratamiento.Material y métodos. Se hizo un estudio transversal analítico en pacientes con diabetes mellitus de tipo 2, hiperglucemia (superior o igual al 7 % de la hemoglobina glucosilada, HbA1C) y con diagnóstico clínico de candidiasis oral. Mediante técnicas microbiológicas, se identificaron las especies causales de la candidiasis oral. Las pruebas de sensibilidad se llevaron a cabo con el método de difusión en placa con tiras (E-test®).Resultados. Se incluyeron 72 pacientes: 32 (44 %) hombres y 40 (56 %) mujeres, clasificados en tres grupos de edad: jóvenes adultos (17 %), adultos (74 %) y ancianos (9 %), con una media de 51 años. No se encontraron diferencias significativas en la candidiasis oral según los grupos de sexo y edad, ni entre las candidiasis orales mixtas y el sexo, el porcentaje de HbA1C, el tratamiento antihiperglucemiante o el tiempo de diagnóstico de la diabetes mellitus de tipo 2. En el grupo etario de adultos, se encontró una correlación con las candidiasis mixtas o simples. Se encontraron 8 (13 %) casos de candidiasis mixtas: siete con coinfección por dos especies de Candida y uno con coinfección por tres especies. Las especies identificadas en ellos, fueron: Candida albicans, C. glabrata, C. dubliniensis, C. kefyr, C. tropicalis y C. krusei. La mayoría de estas especies presentó sensibilidad a ketoconazol y fluconazol, y mayor resistencia a itraconazol.Conclusiones. Las candidiasis orales mixtas se presentan, aproximadamente, en el 10 % de los pacientes con diabetes mellitus de tipo 2 y el tratamiento puede ser ineficaz cuando no se identifica el agente etiológico.